{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"The RP2D of abemaciclib was determined based on the totality of safety, tolerability, and pharmacokinetic results. RP2D of abemaciclib in combination with 50 mg/m²/day irinotecan and 100 mg/m²/day temozolomide on days 1-5 of 21-day cycles was reported.","groups":[{"description":"* Cohort A1: 70 mg/m² abemaciclib administered orally BID in combination with 50 mg/m²/day irinotecan administered IV on Days 1-5 of each 21-day cycle and 100 mg/m²/day temozolomide administered orally on Days 1-5 of each 21-day cycle.\n* Cohort A-1: 55 mg/m² abemaciclib administered orally BID in combination with 50 mg/m²/day irinotecan administered IV on Days 1-5 of each 21-day cycle and 100 mg/m²/day temozolomide administered orally on Days 1-5 of each 21-day cycle.","id":"OG000","title":"Part A - Abemaciclib"}],"paramType":"NUMBER","populationDescription":"All participants in Part A who received at least one dose of abemaciclib and had evaluable data for this outcome.","reportingStatus":"POSTED","timeFrame":"Cycles 1 and 2 (21 Day Cycles)","title":"Recommended Phase 2 Dose (RP2D) of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A)","type":"PRIMARY","unitOfMeasure":"milligrams/squared meters (mg/m²) BID"}